| Drug General Information |
| Drug ID |
D0G7IV
|
| Former ID |
DIB009389
|
| Drug Name |
Premarin/Pravachol
|
| Synonyms |
Estrogen/pravastatin
|
| Indication |
Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78]
|
Phase 3 |
[1]
|
|---|
| Company |
Bristol-Myers Squibb
|
| Target and Pathway |
| Target(s) |
Estrogen receptor beta |
Target Info |
Modulator |
[1]
|
|---|
| Estrogen receptor |
Target Info |
Modulator |
[1]
|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
Target Info |
Modulator |
[1]
|
|
BioCyc Pathway
|
Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
|
|
Superpathway of cholesterol biosynthesis
|
|
Mevalonate pathway
|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathwayhsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancerhsa00900:Terpenoid backbone biosynthesis
|
|
Metabolic pathways
|
|
Biosynthesis of antibiotics
|
|
AMPK signaling pathway
|
|
Bile secretion
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
TSH Signaling Pathway
|
|
PANTHER Pathway
|
Cholesterol biosynthesis
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated nuclear estrogen receptor beta network
|
|
Validated nuclear estrogen receptor alpha networksmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor network
|
|
PathWhiz Pathway
|
Steroid Biosynthesis
|
|
Reactome
|
Nuclear Receptor transcription pathwayR-HSA-1251985:Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Ovarian Infertility Genes
|
|
Integrated Pancreatic Cancer Pathway
|
|
Nuclear ReceptorsWP712:Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear ReceptorsWP430:Statin Pathway
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
SREBP signalling
|
|
Cholesterol Biosynthesis
|
| References |
| REF 1 | Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. |
|---|
